Enteric Hyperoxaluria
9
1
1
5
Key Insights
Highlights
Success Rate
71% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 77/100
22.2%
2 terminated out of 9 trials
71.4%
-15.1% vs benchmark
22%
2 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (9)
Gut Kidney Axis in Enteric Hyperoxaluria
Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria
Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects
Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel Syndrome
Safety and Tolerability of FB-001 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria
Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria
Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia
Enteric Oxalate Absorption Study in Unclassified Hyperoxaluria
Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria